SUPER MICRO WKN: A0MKJF ISIN: US86800U1043 Forum: Aktien Thema: Hauptdiskussion

Kommentare 50.991
Ezoon
Ezoon, 13.05.2022 22:30 Uhr
0
Kennt keiner.
PaT176
PaT176, 11.05.2022 7:38 Uhr
0
Warum ist hier nichts los?
Ezoon
Ezoon, 04.05.2022 21:43 Uhr
0
Hallo zusammen. Bin seit heute Mittag dabei und 10% im Plus. Das ist eine kleine versteckt Perle, die die nächsten Jahre eine Menge Spass machen wird. Bin auf die Aktie durch einen Artikel des stlv. Chefredakteurs von GodMode Trader gekommen.
S
SirDnk, 04.05.2022 19:35 Uhr
1
Die Neubewertung von SuperMicro startet. Mit zunehmender Aufmerksamkeit werden wir Ende des Jahres mit hoher Wahrscheinlichkeit dreistellige Kurse sehen, spring auf den Zug wer kann ;-)
Dinmalo
Dinmalo, 04.05.2022 19:35 Uhr
0
Supermicro Announces Third Quarter Fiscal Year 2022 Financial Results 05/03/2022 SAN JOSE, Calif.--(BUSINESS WIRE)-- Super Micro Computer, Inc. (Nasdaq: SMCI), a global leader in high-performance, high-efficiency server and storage technology and green computing, today announced financial results for its third quarter of fiscal year 2022 ended March 31, 2022. Third Quarter Fiscal Year 2022 Highlights Net sales of $1.36 billion versus $1.17 billion in the second quarter of fiscal year 2022 and $896 million in the same quarter of last year.Gross margin of 15.5% versus 14.0% in the second quarter of fiscal year 2022 and 13.7% in the same quarter of last year.Net income of $77 million versus $42 million in the second quarter of fiscal year 2022 and $18 million in the same quarter of last year.Diluted net income per common share of $1.43 versus $0.78 in the second quarter of fiscal year 2022 and $0.35 in the same quarter of last year.Non-GAAP diluted net income per common share of $1.55 versus $0.88 in the second quarter of fiscal year 2022 and $0.50 in the same quarter of last year.Cash flow used in operations for the third quarter of fiscal year 2022 of $228 million and capital expenditures of $11 million. Non-GAAP gross margin for the third quarter of fiscal year 2022 was 15.6%, which adds back stock-based compensation expenses of $0.5 million. Non-GAAP diluted net income per common share for the third quarter of fiscal year 2022 was $1.55, which adds back stock-based compensation expenses of $7.7 million, litigation expenses of $2.2 million, and $2.0 million of litigation settlement costs net of the related tax effects. As of March 31, 2022, total cash and cash equivalents was $247 million and total bank debt was $547 million. “This is Supermicro’s fourth consecutive quarter of revenues exceeding a billion dollars and with a trailing four quarter revenue run rate of $4.6 billion, it gives me strong confidence that we are well ahead of our long-term targets,” said Charles Liang, Chairman and CEO. “Our robust growth and EPS progress demonstrates the efficiency of our global operational leverage and our customers recognizing the value of our rack-scale Total IT Solutions in key market segments across AI, enterprise, cloud, edge/telco and others. Along with our product optimization, time to market advantage, and green computing cost-savings presented by our Total IT Solutions, our growth momentum should continue to fuel our emergence as the leading company in the industry in the coming quarters and years ahead.” Business Outlook and Management Commentary For the fourth quarter of fiscal year 2022 ending June 30, 2022, the Company expects net sales of $1.4 billion to $1.48 billion, GAAP net income per diluted share of $1.45 to $1.64 and non-GAAP net income per diluted share of $1.51 to $1.69. The Company’s projections for GAAP and non-GAAP net income per diluted share assume a tax rate of approximately 17.4% and 19.4%, respectively, and a fully diluted share count of 54.3 million shares for GAAP and fully diluted share count of 55.7 million shares for non-GAAP. The outlook for Q4 of fiscal year 2022 GAAP net income per diluted share includes approximately $8.0 million in expected stock-based compensation expense and $1.0 million in other expenses that are excluded from non-GAAP net income per diluted share. For fiscal year 2022 ending June 30, 2022, the Company raises its previous guidance of net sales from $4.2 billion to $4.6 billion to a new range of $4.96 billion to $5.04 billion, and raises its GAAP net income per diluted share of at least $2.77 to a new range of $4.16 to $4.35.
Soulfinger
Soulfinger, 04.05.2022 18:13 Uhr
0
Mega Zahlen
P
Patrick119, 04.05.2022 16:48 Uhr
0
Super!
T
Tonimaus, 04.05.2022 14:56 Uhr
0
WOW 🤩
S
SirDnk, 19.04.2022 21:59 Uhr
0
Werden Sie, da bin ich absolut überzeugt. Die werden die nächsten 3 Jahre noch richtig Spaß machen.
T
Tonimaus, 19.04.2022 17:33 Uhr
0
Hammer Kursanstieg heute🚀 Hoffentlich kann SMC die guten Prognosen am 3. Mai bestätigen.
Z
Zehnerssucht10, 19.04.2022 17:23 Uhr
0
Jawoll danke
M
Malcom1893, 19.04.2022 3:43 Uhr
1
Prognose deutlich angehoben. :) https://finance.yahoo.com/news/supermicro-provides-third-quarter-fiscal-201900501.html
Soulfinger
Soulfinger, 19.01.2022 22:57 Uhr
0
Außer das zur Info. Die Zahlen kommen am 1.2. https://ir.supermicro.com/news/news-details/2022/Supermicro-Schedules-Conference-Call-and-Webcast-for-Second-Quarter-Fiscal-2022-Financial-Results/default.aspx
Soulfinger
Soulfinger, 19.01.2022 22:56 Uhr
0
Konnte nichts finden bisher
Z
Zehnerssucht10, 19.01.2022 21:03 Uhr
0
Und heut 7 runter
Mehr zu diesem Wert
Thema
1 SUPER MICRO Hauptdiskussion
2 SMCI Stammtisch (sachlich/informativ)
3 Wirecard 2.0
Meistdiskutiert
Thema
1 Goldpreis Hauptdiskussion ±0,00 %
2 Lilium Aktie -27,46 %
3 GAMESTOP Hauptdiskussion +0,10 %
4 Trading- und Aktien-Chat
5 BTC/USD Hauptdiskussion -3,33 %
6 BED BATH & BEYOND Hauptdiskussion ±0,00 %
7 Nantkwest / Immunitybio -> IBRX +26,60 %
8 NEL ASA Hauptdiskussion -2,15 %
9 Renk Group +0,23 %
10 CHINA MOBILE Hauptdiskussion -0,59 %
Alle Diskussionen
Aktien
Thema
1 Lilium Aktie -27,46 %
2 GAMESTOP Hauptdiskussion +0,10 %
3 BED BATH & BEYOND Hauptdiskussion ±0,00 %
4 Renk Group +0,23 %
5 CHINA MOBILE Hauptdiskussion -0,59 %
6 CrowdStrike Holdings Registered (A) Hauptdiskussion -1,40 %
7 APPLE Hauptdiskussion +0,36 %
8 Nantkwest / Immunitybio -> IBRX +26,60 %
9 NEL ASA Hauptdiskussion -2,15 %
10 Xpeng +6,73 %
Alle Diskussionen